World Health Organization recommends systemic corticosteroids for treatment of severe, critical COVID-19

World Health Organization recommends systemic corticosteroids for treatment of severe, critical COVID-19

A new analysis of several studies in which steroid drugs were used to treat severely ill COVID-19 patients found the drugs significantly helped reduce patient deaths, bolstering earlier, preliminary evidence for the benefit of these medications.

REMAP-CAP is one of seven randomised control trials to test corticosteroids for treating Covid-19 in critically-ill patients. Participants were divided into two arms: 678 received corticosteroids and 1,025 received standard care or placebo. In early June, researchers announced that a common, low-priced steroid called dexamethasone reduced the risk of death among patients with severe cases of Covid-19, giving some hope that widely available steroids could be an effective treatment for such patients.

Professor Jonathan Van-Tam, deputy chief medical officer, said: "These findings offer further evidence that corticosteroids can be an important part of Covid-19 treatment for severe patients".

The CoDEX multicenter, open-label trial randomized 299 patients in Brazil with COVID-19 and moderate to severe acute respiratory distress syndrome (ARDS) by the Berlin definition to 20-mg IV dexamethasone daily for 5 days, then 10 mg daily for 5 days or until ICU discharge atop standard care or to standard care alone.

As researchers and biotech companies are fast-tracking the COVID-19 vaccine development process, the World Health Organization (WHO) which has been tracking potential vaccine candidates, has recommended doctors to use anti-inflammatory drugs corticosteroids to treat Coronavirus patients. "For patients who were not treated with this steroid, around 40% of them died from a severe form of Covid-19", explained Anthony Gordon.

Treatment guidelines in the USA now recommend dexamethasone or other only when it's not available for hospitalized COVID-19 patients needing extra oxygen, but that could change with new information.

Treatment guidelines in the US now recommend dexamethasone or others only when it's not available for hospitalized COVID-19 patients needing extra oxygen, but that could change with the new information. The study considered data from 403 patients at 88 hospitals for its assessment. The patient population included participants of mixed ethnicities in the UK, Ireland, Australia, the U.S., the Netherlands, New Zealand, Canada and France.

Corticosteroids - a cheap and widely available class of drugs - can help people with serious cases of COVID-19 survive, according to trial results published this week. They also compared the results of the United Kingdom study with those of six others around the world. These newly-published results back up dexamethasone as a way to improve recovery rates and decrease recovery time.

"Taking the data from all the seven trials combined in the patients who weren't treated with steroids".

The steroids in the trials included methylprednisolone, hydrocortisone, and dexamethasone. Researchers from three research groups have now published their findings that they had gathered in the journal JAMA.

Related Articles